Curaleaf International and Jupiter Research Secure EU Certification for Pioneering Handheld Liquid Inhalation Device

Partnership Pioneers the First-Ever Certified Handheld Liquid Inhalation Device for Medical Use in Europe, Expanding Access to Innovative Treatment Options.

The approval of Curaleaf International’s handheld liquid inhalation device marks a pivotal moment for medical cannabis delivery, reflecting a significant leap in precision healthcare. With the device now certified as a Class IIa medical device in Europe, it demonstrates the commitment to providing patients with a regulated and consistent treatment method. This approval not only complies with the rigorous standards set by European regulators but also sets a new precedent for medical cannabis devices globally. By ensuring a controlled cannabinoid delivery, the device offers healthcare providers a reliable tool for administering medical cannabis, addressing the increasing demand for precise and accessible patient care.

This innovative device is a breakthrough in medical cannabis technology, combining convenience with clinical effectiveness. The rechargeable power supply and magnetic snap-in cartridge system allow for a seamless, user-friendly experience, making it easier for patients to manage their treatment. The device's EU certification highlights the advanced engineering behind the product, developed by Curaleaf International and Jupiter Research. With its precise dosage control, it eliminates the inconsistencies associated with other cannabis consumption methods, ensuring better therapeutic outcomes. Its approval underscores the growing role of cannabis in mainstream healthcare, providing both patients and doctors with an improved option for treatment.

In conclusion, the EU medical device certification opens the door to global market expansion, positioning Curaleaf International as a leader in the medical cannabis industry. By meeting the highest standards of safety, quality, and clinical robustness, the device is poised to transform how medical cannabis is delivered across Europe, the UK, Canada, and beyond. This achievement further underscores Curaleaf’s dedication to advancing patient care through innovative technology, ultimately helping improve lives with an effective, discreet, and precise treatment option.


MedTech Spectrum's Summary
 
Regulatory Milestone: Curaleaf International’s handheld liquid inhalation device has received EU medical device certification (Class IIa), meeting stringent European safety and quality standards, positioning it as a leader in the medical cannabis market.
 
Innovation in Cannabis Delivery: The device offers precise, controlled cannabinoid delivery with user-friendly features such as a magnetic snap-in cartridge and rechargeable power supply, ensuring consistent treatment for patients.
 
Global Expansion Potential: The EU certification opens doors for Curaleaf to deploy the device across multiple international markets, enhancing patient care in Europe, the UK, Canada, and beyond, while reinforcing the company’s commitment to advancing medical cannabis accessibility.